A Phase 3 interventional study of ART and DOR/ISL in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 53 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the antiretroviral activity of a switch to DOR/ISL compared with continued baseline ART at Week 48. The primary hypothesis is that DOR/ISL is non-inferior to continued baseline ART, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months who were previously treated with continuous baseline antiretroviral therapy (ART) receive doravine/islatravir (DOR/ISL), a fixed dose combination (FDC) of 100 mg DOR/0.25 mg ISL orally once daily (qd) for 144 weeks. At Week 144, participants who consent to enter the optional study extension will continue to receive DOR/ISL qd (100 mg/0.25 mg) for an additional 96 weeks or until it is commercially accessible (whichever comes first).
Drug: DOR/ISL
Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months who were previously treated with continuous baseline ART received standard of care (SOC) ART for 48 weeks, followed by treatment with DOR/ISL as a FDC of 100 mg DOR/0.25 mg ISL orally qd until Week 144. At Week 144, participants who consent to enter the optional study extension will continue to receive DOR/ISL qd (100 mg/0.25 mg) for an additional 96 weeks or until it is commercially accessible (whichever comes first).
Drug: ART
Standard of care ART, per approved product list, taken orally
Drug pages: Doravirine · Islatravir
Single tablet combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
Also known as: MK-8591A
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48
HIV-1 RNA levels in plasma were measured by polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
Time frame: Week 48
Percentage of Participants With One or More Adverse Events (AEs) at Week 48
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 48 are reported.
Time frame: Up to Week 48
Percentage of Participants With an AE Leading to Discontinuation of Study Intervention at Week 48
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 48 are reported.
Time frame: Up to Week 48
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.
Time frame: Week 96
Participants With HIV-1 RNA <200 Copies/mL at Week 144
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.
Time frame: Week 144
Mean Change of Plasma Cluster of Differentiation 4 (CD4+) T-Cell Count From Baseline Day 1 to Week 48
Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The mean change of plasma CD4+ T-Cell count from baseline to Week 48 is presented.
Time frame: Baseline at Day 1 and Week 48
Mean Change of Plasma CD4+ T-Cell Count From Baseline Week 48 to Week 96
Mean change from baseline at Week 48 in CD4+ T-cell count at Week 96. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.
Time frame: Baseline at Week 48 and Week 96
Mean Change of Plasma CD4+ T-Cell Count From Baseline Day 48 to Week 144
Mean change from baseline at Week 48 in CD4+ T-cell count at Week 144. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.
Time frame: Baseline at Week 48 and Week 144
Mean Change of Plasma CD4+ T-Cell Count From Baseline Day 1 to Week 96
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.
Time frame: Baseline at Day 1 and Week 96
Mean Change of Plasma CD4+ T-Cell Count From Baseline Day 1 to Week 144
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.
Time frame: Baseline at Day 1 and Week 144
Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48
Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA \>=200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA \>=200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Participants with HIV-1 RNA \>=400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.
Time frame: Up to Week 48
Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48
Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Low density lipoprotein cholesterol (LDL-C) at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.
Time frame: Baseline and Week 48
Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48
Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Non-HDL-C at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.
Time frame: Baseline and Week 48
Participants With One or More AEs at Week 96
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 96 is reported.
Time frame: Up to Week 96
Participants With One or More AEs at Week 144
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 144 is reported.
Time frame: Up to Week 144
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention at Week 96
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 96 are reported.
Time frame: Up to Week 96
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention at Week 144
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 144 are reported.
Time frame: Up to Week 144
Percentage of Participants With One or More AEs From Week 48 up to Week 96
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 96 is reported.
Time frame: Week 48 up to Week 96
Percentage of Participants With One or More AEs From Week 48 up to Week 144
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 144 is presented.
Time frame: Week 48 up to Week 144
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention From Week 48 up to Week 96
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 96 are reported.
Time frame: Week 48 up to Week 96
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention From Week 48 up to Week 144
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 144 are reported.
Time frame: Week 48 up to Week 144
Adults living with human immunodeficiency virus-1 (HIV-1) receiving baseline antiretroviral therapy (ART) were enrolled.
| Milestone | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Started | 368 | 185 |
| Treated | 366 | 185 |
| Completed | 9 | 3 |
| Not completed | 359 | 182 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Ongoing | 353 | 177 |
| Withdrew: Adverse event | 0 | 1 |
HIV-1 RNA levels in plasma were measured by polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
| Percentage of Participants | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48 | 1.4 | 4.9 |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 48 are reported.
| Percentage of Participants | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Percentage of Participants With One or More Adverse Events (AEs) at Week 48 | 79.5 | 83.8 |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 48 are reported.
| Percentage of Participants | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Percentage of Participants With an AE Leading to Discontinuation of Study Intervention at Week 48 | 0.5 | 2.2 |
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
| Percentage of Participants | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48 | 95.6 | 95.7 |
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
| Percentage of Participants | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 | 95.6 | 91.9 |
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.
Results for this outcome have not been posted.
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.
Results for this outcome have not been posted.
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.
Results for this outcome have not been posted.
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.
Results for this outcome have not been posted.
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.
Results for this outcome have not been posted.
HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.
Results for this outcome have not been posted.
Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The mean change of plasma CD4+ T-Cell count from baseline to Week 48 is presented.
| cells/mm^3 | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Mean Change of Plasma Cluster of Differentiation 4 (CD4+) T-Cell Count From Baseline Day 1 to Week 48 | 5.41 (-12.11 to 22.94) | 18.22 (-11.84 to 48.28) |
Mean change from baseline at Week 48 in CD4+ T-cell count at Week 96. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.
Results for this outcome have not been posted.
Mean change from baseline at Week 48 in CD4+ T-cell count at Week 144. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.
Results for this outcome have not been posted.
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.
Results for this outcome have not been posted.
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.
Results for this outcome have not been posted.
Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA \>=200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA \>=200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Participants with HIV-1 RNA \>=400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.
| Percentage of participants | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48 | 0 | — |
Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Low density lipoprotein cholesterol (LDL-C) at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.
| mg/dL | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| PI-containing regimens (including PI- + InSTI-containing regimens) | -7.10 (-27.06 to 12.86) | -2.75 (-9.91 to 4.41) |
| non-PI- and non-InSTI-containing regimens | 5.07 (-0.77 to 10.91) | 0.29 (-5.92 to 6.50) |
| InSTI-containing regimens (non-PI-containing regimens) | 2.45 (-0.73 to 5.63) | -0.37 (-5.02 to 4.28) |
Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Non-HDL-C at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.
| mg/dL | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| PI-containing regimens (including PI- + InSTI-containing regimens) | -11.80 (-32.04 to 8.44) | -2.75 (-10.90 to 5.40) |
| non-PI- and non-InSTI-containing regimens | 5.78 (-0.40 to 11.97) | 0.44 (-6.47 to 7.35) |
| InSTI-containing regimens (non-PI-containing regimens) | 3.60 (0.06 to 7.14) | 3.29 (-5.87 to 12.44) |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 96 is reported.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 144 is reported.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 96 are reported.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 144 are reported.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 96 is reported.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 144 is presented.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 96 are reported.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 144 are reported.
Results for this outcome have not been posted.
Collected over All-cause mortality and adverse events up to 48 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doravirine/Islatravir (DOR/ISL) | 0/368 (0%) | 23/366 (6.3%) | 123/366 (33.6%) |
| Baseline ART + DOR/ISL | 1/185 (0.5%) | 9/185 (4.9%) | 73/185 (39.5%) |
| Event | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| PneumoniaInfections and infestations | 3/366 | 0/185 |
| Atrial fibrillationCardiac disorders | 2/366 | 0/185 |
| AgranulocytosisBlood and lymphatic system disorders | 0/366 | 1/185 |
| Blood loss anaemiaBlood and lymphatic system disorders | 0/366 | 1/185 |
| CellulitisInfections and infestations | 0/366 | 1/185 |
| Viral upper respiratory tract infectionInfections and infestations | 0/366 | 1/185 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/366 | 1/185 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/366 | 1/185 |
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/366 | 1/185 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/366 | 1/185 |
| Event | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 38/366 | 25/185 |
| DiarrhoeaGastrointestinal disorders | 29/366 | 3/185 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/366 | 14/185 |
| HeadacheNervous system disorders | 19/366 | 14/185 |
| NasopharyngitisInfections and infestations | 20/366 | 12/185 |
| COVID-19Infections and infestations | 14/366 | 10/185 |
| Back painMusculoskeletal and connective tissue disorders | 18/366 | 10/185 |
| Age, Continuous(Years) | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL | Total |
|---|---|---|---|
| Mean | 49.9 ± 12.6 | 49.5 ± 11.8 | 49.8 ± 12.3 |
| Sex: Female, Male(Participants) | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL | Total |
|---|---|---|---|
| Female | 152 | 67 | 219 |
| Male | 216 | 118 | 334 |
| Ethnicity (NIH/OMB)(Participants) | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL | Total |
|---|---|---|---|
| Hispanic or Latino | 54 | 26 | 80 |
| Not Hispanic or Latino | 310 | 157 | 467 |
| Unknown or Not Reported | 4 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 18 | 10 | 28 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 166 | 84 | 250 |
| White | 143 | 74 | 217 |
| More than one race | 38 | 16 | 54 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Baseline Antiretroviral (ART) Stratification at Randomization(Count of Participants) | Doravirine/Islatravir (DOR/ISL) | Baseline ART + DOR/ISL | Total |
|---|---|---|---|
| PI-containing regimens (including PI- and InSTI-containing regimens) | 22 | 8 | 30 |
| InSTI-based regimens (non-PI containing regimens) | 233 | 121 | 354 |
| All other non-PI- and non-InSTI containing regimens | 111 | 56 | 167 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2023 to primary completion in Oct 2024, 19 months.
Results were first posted in Nov 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir